Innovative Partnership in Cancer Treatment
Anbogen, a biotech company known for its clinical prowess, has announced an exciting collaboration aimed at improving treatment options for colorectal cancer. This partnership involves the evaluation of Anbogen's HDAC inhibitor, ABT-301, combined with BeiGene's anti-PD-1 antibody, tislelizumab. This combination therapy is particularly relevant for patients dealing with mismatch repair–proficient (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC), which represents a significant portion of colorectal cancer patients.
Understanding the Unmet Needs in Colorectal Cancer
Colorectal cancer continues to be a major health challenge, with over 1.9 million new cases diagnosed annually worldwide. While immune checkpoint inhibitors have transformed the landscape for some patients, their effectiveness is limited predominantly to those with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). Unfortunately, this only accounts for less than five percent of mCRC cases. The overwhelming majority, approximately 95%, have pMMR/MSS tumors, leaving a gaping hole in available treatment options.
Potential of ABT-301 in Combination Therapy
ABT-301 emerges as a promising candidate in the fight against colorectal cancer. Previous studies have showcased its safety and pharmacokinetic properties in initial Phase 1 trials. Preclinical evidence suggests that ABT-301 not only improves the effects of existing anti-PD-1 and anti-PD-L1 therapies but also promotes a more robust immune response. This is achieved by enhancing the proliferation of CD8+ cytotoxic T cells while simultaneously reducing the presence of monocytic myeloid-derived suppressor cells. Thus, ABT-301 aids in creating an environment less conducive to tumor growth.
The Clinical Trial and Its Significance
The forthcoming Phase II clinical trial, a pivotal step in the research of this combination approach, aims to evaluate the safety, tolerability, and preliminary effectiveness of combining ABT-301 and tislelizumab. There will also be a focus on how these therapies perform in conjunction with Bevacizumab. This study is not just about examining new treatment options; it is about addressing the significant unmet medical needs of those suffering from advanced MSS colorectal cancer.
Leadership Vision for Future Oncology Treatments
CEO John Hsu expressed enthusiasm about the collaboration, emphasizing the potential benefits that this combination therapy could provide for colorectal cancer patients. With a scientific team and a research-driven mindset, Anbogen aims to be at the forefront of innovative cancer treatments. Their commitment is evident in their ongoing research and clinical trials, including the promising developments of ABT-101 targeting non-small cell lung cancer (NSCLC).
About Anbogen
Anbogen is not just another biotech entity but a clinical-stage company focused on the creation of precision anti-cancer medications. They successfully completed a $20 million Series A funding round recently, allocating funds towards research and development innovations. Founded by Dr. Joe Shih, Anbogen is positioned strategically within the biotechnology industry, leveraging years of experience from its team, many of whom have previously contributed to significant advancements in drug development.
Frequently Asked Questions
What is the collaboration about?
Anbogen has partnered with BeiGene to explore a combination therapy using ABT-301 and tislelizumab for patients with metastatic colorectal cancer.
Why is this trial important?
This trial addresses the needs of a large group of colorectal cancer patients who have limited effective treatment options available to them.
What are the expected outcomes of the trial?
The trial aims to determine the safety, tolerability, and preliminary effectiveness of the drug combination in patients with advanced MSS colorectal cancer.
Who leads Anbogen?
Anbogen is led by CEO John Hsu, who is optimistic about the potential impacts of this partnership on cancer treatment.
What other projects are underway at Anbogen?
In addition to the collaboration with BeiGene, Anbogen is also developing ABT-101 for non-small cell lung cancer patients.
